Potential Hormone Mechanisms of Bariatric Surgery

Georgios K Dimitriadis, Manpal S Randeva, Alexander D Miras, Georgios K Dimitriadis, Manpal S Randeva, Alexander D Miras

Abstract

Purpose of review: In recent years, the role of the gastrointestinal (GI) tract in energy homeostasis through modulation of the digestion and absorption of carbohydrates and the production of incretin hormones is well recognized.

Recent findings: Bariatric surgery for obesity has been a very effective method in substantially improving weight, and numerous studies have focused on intestinal adaptation after bariatric procedures. A number of structural and functional changes in the GI tract have been reported postsurgery, which could be responsible for the altered hormonal responses. Furthermore, the change in food absorption rate and the intestinal regions exposed to carbohydrates may affect blood glucose response. This review hopes to give new insights into the direct role of gut hormones, by summarising the metabolic effects of bariatric surgery.

Keywords: Bariatric surgery; CCK; FGF19; FGF21; GIP; GLP-1; GLP-2; Gastric banding; Gastrin; Ghrelin; Glucagon; Gustducin; Gut hormones; Insulin; Obestatin; Oxyntomodulin; PP; PYY; Roux-en-Y gastric bypass; Secretin; Sleeve gastrectomy; Somatostatin; VIP.

Conflict of interest statement

Conflict of Interest

Georgios K. Dimitriadis, Manpal S. Randeva and Alexander D. Miras declare they have no conflict of interest.

Human and Animal Rights and Informed Consent

This article does not contain any studies with human or animal subjects performed by any of the authors.

Figures

Fig. 1
Fig. 1
Hormone interactions (feedback mechanisms) between the brain and organs of the gastrointestinal tract

References

    1. Finucane MM, Stevens GA, Cowan MJ, et al. National, regional, and global trends in body-mass index since 1980: systematic analysis of health examination surveys and epidemiological studies with 960 country-years and 9.1 million participants. Lancet. 2011;377:557–567. doi: 10.1016/S0140-6736(10)62037-5.
    1. Cavin JB, Bado A, Le Gall M. Intestinal adaptations after bariatric surgery: consequences on glucose homeostasis. Trends Endocrinol Metab. 2017;28(5):354–364. doi: 10.1016/j.tem.2017.01.002.
    1. Evers SS, Sandoval DA, Seeley RJ. The physiology and molecular underpinnings of the effects of bariatric surgery on obesity and diabetes. Annu Rev Physiol. 2017;79:313–334. doi: 10.1146/annurev-physiol-022516-034423.
    1. Sharples AJ, Charalampakis V, Daskalakis M, Tahrani AA, Singhal R. Systematic review and meta-analysis of outcomes after revisional bariatric surgery following a failed adjustable gastric band. Obes Surg. 2017; doi:10.1007/s11695-017-2677-7.
    1. Golzarand M, Toolabi K, Farid R. The bariatric surgery and weight losing: a meta-analysis in the long- and very long-term effects of laparoscopic adjustable gastric banding, laparoscopic Roux-en-Y gastric bypass and laparoscopic sleeve gastrectomy on weight loss in adults. Surg Endosc. 2017; doi:10.1007/s00464-017-5505-1.
    1. Magouliotis DE, Tasiopoulou VS, Svokos AA, Svokos KA, Sioka E, Zacharoulis D. Roux-en-Y gastric bypass versus sleeve gastrectomy as revisional procedure after adjustable gastric band: a systematic review and meta-analysis. Obes Surg. 2017;27(5):1365–1373. doi: 10.1007/s11695-017-2644-3.
    1. Jacobsen SH, Olesen SC, Dirksen C, Jørgensen NB, Bojsen-Møller KN, Kielgast U, et al. Changes in gastrointestinal hormone responses, insulin sensitivity, and beta-cell function within 2 weeks after gastric bypass in non-diabetic subjects. Obes Surg. 2012;22(7):1084–1096. doi: 10.1007/s11695-012-0621-4.
    1. Sundbom M, Holdstock C, Engström BE, Karlsson FA. Early changes in ghrelin following Roux-en-Y gastric bypass: influence of vagal nerve functionality ? Obes Surg. 2007;17(3):304–310. doi: 10.1007/s11695-007-9056-8.
    1. Safatle-Ribeiro AV, Petersen PA, Pereira Filho DS, Corbett CE, Faintuch J, Ishida R, et al. Epithelial cell turnover is increased in the excluded stomach mucosa after Roux-en-Y gastric bypass for morbid obesity. Obes Surg. 2013;23(10):1616–1623. doi: 10.1007/s11695-013-0975-2.
    1. Hedberg J, Hedenström H, Nilsson S, Sundbom M, Gustavsson S. Role of gastric acid in stomal ulcer after gastric bypass. Obes Surg. 2005;15(10):1375–1378. doi: 10.1381/096089205774859380.
    1. Grong E, Græslie H, Munkvold B, Arbo IB, Kulseng BE, Waldum HL, Mårvik R. Gastrin secretion after bariatric surgery-response to a protein-rich mixed meal following Roux-en-Y gastric bypass and sleeve gastrectomy: a pilot study in normoglycemic women. Obes Surg. 2016;26(7):1448–1456. doi: 10.1007/s11695-015-1985-z.
    1. Shak JR, Roper J, Perez-Perez GI, Tseng CH, Francois F, Gamagaris Z, et al. The effect of laparoscopic gastric banding surgery on plasma levels of appetite-control, insulinotropic, and digestive hormones. Obes Surg. 2008;18(9):1089–1096. doi: 10.1007/s11695-008-9454-6.
    1. Sillakivi T, Suumann J, Kirsimägi U, Peetsalu A. Plasma levels of gastric biomarkers in patients after bariatric surgery: biomarkers after bariatric surgery. Hepato-Gastroenterology. 2013;60(128):2129–2132.
    1. Grong E, Arbo IB, Thu OK, Kuhry E, Kulseng B, Mårvik R. The effect of duodenojejunostomy and sleeve gastrectomy on type 2 diabetes mellitus and gastrin secretion in Goto-Kakizaki rats. Surg Endosc. 2015;29(3):723–733. doi: 10.1007/s00464-014-3732-2.
    1. Dickson SL, Egecioglu E, Landgren S, Skibicka KP, Engel JA, Jerlhag E. The role of the central ghrelin system in reward from food and chemical drugs. Mol Cell Endocrinol. 2011;340(1):80–87. doi: 10.1016/j.mce.2011.02.017.
    1. Burger KS, Berner LA. A functional neuroimaging review of obesity, appetitive hormones and ingestive behaviour. Physiol Behav. 2014;136:121–127. doi: 10.1016/j.physbeh.2014.04.025.
    1. Delhanty PJ, van der Lely AJ. Ghrelin and glucose homeostasis. Peptides. 2011;32(11):2309–2318. doi: 10.1016/j.peptides.2011.03.001.
    1. Cummings DE, Weigle DS, Frayo RS, Breen PA, Ma MK, Dellinger EP, et al. Plasma ghrelin levels after diet-induced weight loss or gastric bypass surgery. N Engl J Med. 2002;346(21):1623–1630. doi: 10.1056/NEJMoa012908.
    1. Frühbeck G, Rotellar F, Hernández-Lizoain JL, Gil MJ, Gómez-Ambrosi J, Salvador J, et al. Fasting plasma ghrelin concentrations 6 months after gastric bypass are not determined by weight loss or changes in insulinemia. Obes Surg. 2004;14(9):1208–1215. doi: 10.1381/0960892042386904.
    1. Frühbeck G, Diez-Caballero A, Gil MJ, Montero I, Gómez-Ambrosi J, Salvador J, et al. The decrease in plasma ghrelin concentrations following bariatric surgery depends on the functional integrity of the fundus. Obes Surg. 2004;14(5):606–612. doi: 10.1381/096089204323093363.
    1. Dirksen C, Jørgensen NB, Bojsen-Møller KN, Kielgast U, Jacobsen SH, Clausen TR, et al. Gut hormones, early dumping and resting energy expenditure in patients with good and poor weight loss response after Roux-en-Y gastric bypass. Int J Obes. 2013;37(11):1452–1459. doi: 10.1038/ijo.2013.15.
    1. Yang J, Feng X, Zhong S, Wang Y, Liu J. Gastric bypass surgery may improve beta cell apoptosis with ghrelin overexpression in patients with BMI ≥ 32.5 kg/m2. Obes Surg. 2014;24(4):561–571. doi: 10.1007/s11695-013-1135-4.
    1. Zhou D, Jiang X, Ding W, Zhang D, Yang L, Zhen C, Lu L. Impact of bariatric surgery on ghrelin and obestatin levels in obesity or type 2 diabetes mellitus rat model. J Diabetes Res. 2014;2014:569435.
    1. Yousseif A, Emmanuel J, Karra E, Millet Q, Elkalaawy M, Jenkinson AD, et al. Differential effects of laparoscopic sleeve gastrectomy and laparoscopic gastric bypass on appetite, circulating acylghrelin, peptide YY3–36 and active GLP-1 levels in non-diabetic humans. Obes Surg. 2014;24(2):241–252. doi: 10.1007/s11695-013-1066-0.
    1. Steinert RE, Feinle-Bisset C, Asarian L, Horowitz M, Beglinger C, Ghrelin GN. CCK, GLP-1, and PYY(3-36): secretory controls and physiological roles in eating and glycemia in health, obesity, and after RYGB. Physiol Rev. 2017;97(1):411–463. doi: 10.1152/physrev.00031.2014.
    1. Mans E, Serra-Prat M, Palomera E, Suñol X, Clavé P. Sleeve gastrectomy effects on hunger, satiation, and gastrointestinal hormone and motility responses after a liquid meal test. Am J Clin Nutr. 2015;102(3):540–547. doi: 10.3945/ajcn.114.104307.
    1. Peterli R, Steinert RE, Woelnerhanssen B, Peters T, Christoffel-Courtin C, Gass M, et al. Metabolic and hormonal changes after laparoscopic Roux-en-Y gastric bypass and sleeve gastrectomy: a randomized, prospective trial. Obes Surg. 2012;22(5):740–748. doi: 10.1007/s11695-012-0622-3.
    1. McIntosh CH, Widenmaier S, Kim SJ. Glucose-dependent insulinotropicpolypeptide (gastric inhibitory polypeptide; GIP) Vitam Horm. 2009;80:409–471. doi: 10.1016/S0083-6729(08)00615-8.
    1. Piteau S, Olver A, Kim SJ, Winter K, Pospisilik JA, Lynn F, et al. Reversal ofislet GIP receptor down-regulation and resistance to GIP by reducing hyperglycemia in the Zucker rat. Biochem Biophys Res Commun. 2007;362(4):1007–1012. doi: 10.1016/j.bbrc.2007.08.115.
    1. Guidone C, Manco M, Valera-Mora E, Iaconelli A, Gniuli D, Mari A, et al. Mechanisms of recovery from type 2 diabetes after malabsorptive bariatric surgery. Diabetes. 2006;55(7):2025–2031. doi: 10.2337/db06-0068.
    1. Mingrone G, Nolfe G, Gissey GC, Iaconelli A, Leccesi L, Guidone C, et al. Circadian rhythms of GIP and GLP1 in glucose-tolerant and in type 2 diabetic patients after biliopancreatic diversion. Diabetologia. 2009;52(5):873–881. doi: 10.1007/s00125-009-1288-9.
    1. Salinari S, Bertuzzi A, Asnaghi S, Guidone C, Manco M, Mingrone G. First-phase insulin secretion restoration and differential response to glucose load depending on the route of administration in type 2 diabetic subjects after bariatric surgery. Diabetes Care. 2009;32(3):375–380. doi: 10.2337/dc08-1314.
    1. Bunt JC, Blackstone R, Thearle MS, Vinales KL, Votruba S, Krakoff J. Changes in glycemia, insulin and gut hormone responses to a slowly ingested solid low-carbohydrate mixed meal after laparoscopic gastric bypass or band surgery. Int J Obes. 2017;41(5):706–713. doi: 10.1038/ijo.2017.22.
    1. Korner J, Bessler M, Inabnet W, Taveras C, Holst JJ. Exaggerated glucagon-like peptide-1 and blunted glucose-dependent insulinotropic peptide secretion are associated with Roux-en-Y gastric bypass but not adjustable gastric banding. Surg Obes Relat Dis. 2007;3(6):597–601. doi: 10.1016/j.soard.2007.08.004.
    1. Evans S, Pamuklar Z, Rosko J, Mahaney P, Jiang N, Park C, et al. Gastric bypass surgery restores meal stimulation of the anorexigenic gut hormones glucagon-like peptide-1 and peptide YY independently of caloric restriction. Surg Endosc. 2012;26(4):1086–1094. doi: 10.1007/s00464-011-2004-7.
    1. Shankar SS, Mixson LA, Chakravarthy M, Chisholm R, Acton AJ, Jones R, Mattar SG, Miller DL, Petry L, Beals CR, Stoch SA, Kelley DE, Considine RV. Metabolic improvements following Roux-en-Y surgery assessed by solid meal test in subjects with short duration type 2 diabetes. BMC Obes. 2017;4:10. doi: 10.1186/s40608-017-0149-1.
    1. Tsoli M, Chronaiou A, Kehagias I, Kalfarentzos F, Alexandrides TK. Hormone changes and diabetes resolution after biliopancreatic diversion and laparoscopic sleeve gastrectomy: a comparative prospective study. Surg Obes Relat Dis. 2013;9(5):667–677. doi: 10.1016/j.soard.2012.12.006.
    1. Nausheen S, Shah IH, Pezeshki A, Sigalet DL, Chelikani PK. Effects of sleeve gastrectomy and ileal transposition, alone and in combination, on food intake, body weight, gut hormones, and glucose metabolism in rats. Am J Physiol Endocrinol Metab. 2013;305(4):E507–E518. doi: 10.1152/ajpendo.00130.2013.
    1. Rubino F, Marescaux J. Effect of duodenal-jejunal exclusion in a non-obese animal model of type 2 diabetes: a new perspective for an old disease. Ann Surg. 2004;239(1):1–11. doi: 10.1097/01.sla.0000102989.54824.fc.
    1. Pacheco D, de Luis DA, Romero A, González Sagrado M, Conde R, Izaola O, et al. The effects of duodenal-jejunal exclusion on hormonal regulation of glucose metabolism in Goto-Kakizaki rats. Am J Surg. 2007;194(2):221–224. doi: 10.1016/j.amjsurg.2006.11.015.
    1. Jørgensen NB, Dirksen C, Bojsen-Møller KN, Jacobsen SH, Worm D, et al. Exaggerated glucagon-like peptide 1 response is important for improved beta-cell function and glucose tolerance after Roux-en-Y gastric bypass in patients with type 2 diabetes. Diabetes. 2013;62:3044–3052. doi: 10.2337/db13-0022.
    1. Holst JJ. Postprandial insulin secretion after gastric bypass surgery: the role of glucagon-like peptide 1. Diabetes. 2011;60:2203–2205. doi: 10.2337/db11-0798.
    1. Ye J, Hao Z, Mumphrey MB, Townsend RL, Patterson LM, et al. GLP-1 receptor signaling is not required for reduced body weight after RYGB in rodents. Am J Physiol Regul Integr Comp Physiol. 2014;306:R352–R362. doi: 10.1152/ajpregu.00491.2013.
    1. Wilson-P’erez HE, Chambers AP, Ryan KK, Li B, Sandoval DA, et al. Vertical sleeve gastrectomy is effective in two genetic mouse models of glucagon-like peptide 1 receptor deficiency. Diabetes. 2013;62:2380–2385. doi: 10.2337/db12-1498.
    1. Vilsbøll T, Zdravkovic M, Le-Thi T, Krarup T, Schmitz O, Courrèges JP, et al. Liraglutide, a long-acting human glucagon-like peptide-1 analog, given as monotherapy significantly improves glycemic control and lowers bodyweight without risk of hypoglycemia in patients with type 2 diabetes. Diabetes Care. 2007;30(6):1608–1610. doi: 10.2337/dc06-2593.
    1. Wadden TA, Hollander P, Klein S, Niswender K, Woo V, Hale PM, et al. Weight maintenance and additional weight loss with liraglutide after low-calorie-diet-induced weight loss: the SCALE Maintenance randomized study. Int J Obes. 2013;37(11):1443–1451. doi: 10.1038/ijo.2013.120.
    1. Abbott CR, Monteiro M, Small CJ, Sajedi A, Smith KL, Parkinson JR, et al. The inhibitory effects of peripheral administration of peptide YY(3–36) and glucagon-like peptide-1 on food intake are attenuated by ablation of the vagal-brainstem-hypothalamic pathway. Brain Res. 2005;1044(1):127–131. doi: 10.1016/j.brainres.2005.03.011.
    1. Larsen PJ, Tang-Christensen M, Jessop DS. Central administration of glucagon-like peptide-1 activates hypothalamic neuroendocrine neurons in the rat. Endocrinology. 1997;138(10):4445–4455. doi: 10.1210/endo.138.10.5270.
    1. Turton MD, O’Shea D, Gunn I, Beak SA, Edwards CM, Meeran K, et al. A role for glucagon-like peptide-1 in the central regulation of feeding. Nature. 1996;379(6560):69–72. doi: 10.1038/379069a0.
    1. Bueter M, Miras AD, Chichger H, Fenske W, Ghatei MA, Bloom SR, et al. Alterations of sucrose preference after Roux-en-Y gastric bypass. Physiol Behav. 2011;104(5):709–721. doi: 10.1016/j.physbeh.2011.07.025.
    1. Abalos E, Merialdi M, Wojdyla D, Carroli G, Campodonico L, Yao SE, et al. Effects of calcium supplementation on fetal growth in mothers with deficient calcium intake: a randomised controlled trial. Paediatr Perinat Epidemiol England. 2010;24:53–62. doi: 10.1111/j.1365-3016.2009.01088.x.
    1. Mokadem M, Zechner JF, Margolskee RF, Drucker DJ, Aguirre V. Effects of Roux-en-Y gastric bypass on energy and glucose homeostasis are preserved in two mouse models of functional glucagon-like peptide-1 deficiency. Mol Metab. 2013;3(2):191–201. doi: 10.1016/j.molmet.2013.11.010.
    1. Estall JL, Drucker DJ. Dual regulation of cell proliferation and survival via activation of glucagon-like peptide-2 receptor signaling. J Nutr. 2003;133(11):3708–3711.
    1. Martin GR, Wallace LE, Hartmann B, Holst JJ, Demchyshyn L, Toney K, et al. Nutrient-stimulated GLP-2 release and crypt cell proliferation in experimental short bowel syndrome. Am J Physiol Gastrointest Liver Physiol. 2005;288(3):G431–G438. doi: 10.1152/ajpgi.00242.2004.
    1. Taqi E, Wallace LE, de Heuvel E, Chelikani PK, Zheng H, Berthoud HR, Holst JJ, Sigalet DL. The influence of nutrients, biliary-pancreatic secretions, and systemic trophic hormones on intestinal adaptation in a Roux-en-Y bypass model. J Pediatr Surg. 2010;45(5):987–995. doi: 10.1016/j.jpedsurg.2010.02.036.
    1. le Roux CW, Borg C, Wallis K, Vincent RP, Bueter M, Goodlad R, et al. Gut hypertrophy after gastric bypass is associated with increased glucagon-like peptide 2 and intestinal crypt cell proliferation. Ann Surg. 2010;252(1):50–56. doi: 10.1097/SLA.0b013e3181d3d21f.
    1. Cazzo E, Pareja JC, Chaim EA, Geloneze B, Barreto MR, Magro DO. GLP-1 and GLP-2 levels are correlated with satiety regulation after Roux-en-Y gastric bypass: results of an exploratory prospective study. Obes Surg. 2017;27(3):703–708. doi: 10.1007/s11695-016-2345-3.
    1. Romero F, Nicolau J, Flores L, Casamitjana R, Ibarzabal A, Lacy A, et al. Comparable early changes in gastrointestinal hormones after sleeve gastrectomy and Roux-en-Y gastric bypass surgery for morbidly obese type 2 diabetic subjects. Surg Endosc. 2012;26(8):2231–2239. doi: 10.1007/s00464-012-2166-y.
    1. Cummings BP, Bettaieb A, Graham JL, Stanhope KL, Kowala M, Haj FG, Chouinard ML, Havel PJ. Vertical sleeve gastrectomy improves glucose and lipid metabolism and delays diabetes onset in UCD-T2DM rats. Endocrinology. 2012;153(8):3620–3632. doi: 10.1210/en.2012-1131.
    1. Batterham RL, Cowley MA, Small CJ, Herzog H, Cohen MA, Dakin CL, et al. Gut hormone PYY(3–36) physiologically inhibits food intake. Nature. 2002;418(6898):650–654. doi: 10.1038/nature00887.
    1. Witte AB, Grybäck P, Holst JJ, Hilsted L, Hellström PM, Jacobsson H, et al. Differential effect of PYY1-36 and PYY3-36 on gastric emptying in man. Regul Pept. 2009;158(1–3):57–62. doi: 10.1016/j.regpep.2009.07.013.
    1. Wang L, Gourcerol G, Yuan PQ, Wu SV, Million M, Larauche M, et al. Peripheral peptide YY inhibits propulsive colonic motor function through Y2 receptor in conscious mice. Am J Physiol Gastrointest Liver Physiol. 2010;298(1):G45–G56. doi: 10.1152/ajpgi.00349.2009.
    1. Batterham RL, Cohen MA, Ellis SM, Le Roux CW, Withers DJ, Frost GS, et al. Inhibition of food intake in obese subjects by peptide YY3–36. N Engl J Med. 2003;349(10):941–948. doi: 10.1056/NEJMoa030204.
    1. le Roux CW, Batterham RL, Aylwin SJ, Patterson M, Borg CM, Wynne KJ, et al. Attenuated peptide YY release in obese subjects is associated with reduced satiety. Endocrinology. 2006;147(1):3–8. doi: 10.1210/en.2005-0972.
    1. Dirksen C, Bojsen-Møller KN, Jørgensen NB, Jacobsen SH, Kristiansen VB, Naver LS, et al. Exaggerated release and preserved insulinotropic action of glucagon-like peptide-1 underlie insulin hypersecretion in glucose-tolerant individuals after Roux-en-Y gastric bypass. Diabetologia. 2013;56(12):2679–2687. doi: 10.1007/s00125-013-3055-1.
    1. Korner J, Inabnet W, Febres G, Conwell IM, McMahon DJ, Salas R, et al. Prospective study of gut hormone and metabolic changes after adjustable gastric banding and Roux-en-Y gastric bypass. Int J Obes. 2009;33(7):786–795. doi: 10.1038/ijo.2009.79.
    1. Chandarana K, Gelegen C, Karra E, Choudhury AI, Drew ME, Fauveau V, et al. Diet and gastrointestinal bypass-induced weight loss: the roles of ghrelin and peptide YY. Diabetes. 2011;60(3):810–818. doi: 10.2337/db10-0566.
    1. Laferrère B, Swerdlow N, Bawa B, Arias S, Bose M, Oliván B, et al. Rise of oxyntomodulin in response to oral glucose after gastric bypass surgery in patients with type 2 diabetes. J Clin Endocrinol Metab. 2010;95(8):4072–4076. doi: 10.1210/jc.2009-2767.
    1. Falkén Y, Hellström PM, Holst JJ, Näslund E. Changes in glucose homeostasis after Roux-en-Y gastric bypass surgery for obesity at day three, two months, and one year after surgery: role of gut peptides. J Clin Endocrinol Metab. 2011;96(7):2227–2235. doi: 10.1210/jc.2010-2876.
    1. Pocai A, Carrington PE, Adams JR, Wright M, Eiermann G, Zhu L, et al. Glucagon-like peptide 1/glucagon receptor dual agonism reverses obesity in mice. Diabetes. 2009;58(10):2258–2266. doi: 10.2337/db09-0278.
    1. Day JW, Ottaway N, Patterson JT, Gelfanov V, Smiley D, Gidda J, et al. A new glucagon and GLP-1 co-agonist eliminates obesity in rodents. Nat Chem Biol. 2009;5(10):749–757. doi: 10.1038/nchembio.209.
    1. Wynne K, Park AJ, Small CJ, Patterson M, Ellis SM, Murphy KG, et al. Subcutaneous oxyntomodulin reduces body weight in overweight and obese subjects: a double-blind, randomized, controlled trial. Diabetes. 2005;54(8):2390–2395. doi: 10.2337/diabetes.54.8.2390.
    1. Wynne K, Park AJ, Small CJ, Meeran K, Ghatei MA, Frost GS, et al. Oxyntomodulin increases energy expenditure in addition to decreasing energy intake in overweight and obese humans: a randomised controlled trial. Int J Obes. 2006;30(12):1729–1736. doi: 10.1038/sj.ijo.0803344.
    1. Whitmore TE, Holloway JL, Lofton-Day CE, Maurer MF, Chen L, Quinton TJ, Vincent JB, Scherer SW, Lok S. Human secretin (SCT): gene structure, chromosome location, and distribution of mRNA. Cytogenet Cell Genet. 2000;90(1–2):47–52. doi: 10.1159/000015658.
    1. Rhee NA, Wahlgren CD, Pedersen J, Mortensen B, Langholz E, Wandall EP, Friis SU, Vilmann P, Paulsen SJ, Kristiansen VB, Jelsing J, Dalbøge LS, Poulsen SS, Holst JJ, Vilsbøll T, Knop FK. Effect of Roux-en-Y gastric bypass on the distribution and hormone expression of small-intestinal enteroendocrine cells in obese patients with type 2 diabetes. Diabetologia. 2015;58(10):2254–2258. doi: 10.1007/s00125-015-3696-3.
    1. Nergård BJ, Lindqvist A, Gislason HG, Groop L, Ekelund M, Wierup N, Hedenbro JL. Mucosal glucagon-like peptide-1 and glucose-dependent insulinotropic polypeptide cell numbers in the super-obese human foregut after gastric bypass. Surg Obes Relat Dis. 2015;11(6):1237–1246. doi: 10.1016/j.soard.2015.03.021.
    1. Delgado M, Ganea D. Vasoactive intestinal peptide: a neuropeptide with pleiotropic immune functions. Amino Acids. 2013;45(1):25–39. doi: 10.1007/s00726-011-1184-8.
    1. Batterham RL, Le Roux CW, Cohen MA, Park AJ, Ellis SM, Patterson M, Frost GS, Ghatei MA, Bloom SR. Pancreatic polypeptide reduces appetite and food intake in humans. J Clin Endocrinol Metab. 2003;88(8):3989–3992. doi: 10.1210/jc.2003-030630.
    1. Dixon AF, le Roux CW, Ghatei MA, Bloom SR, McGee TL, Dixon JB. Pancreatic polypeptide meal response may predict gastric band-induced weight loss. Obes Surg. 2011;21(12):1906–1913. doi: 10.1007/s11695-011-0469-z.
    1. Bradley D, Conte C, Mittendorfer B, et al. Gastric bypass and banding equally improve insulin sensitivity and β cell function. J Clin Invest. 2012;122:4667–4674. doi: 10.1172/JCI64895.
    1. Nannipieri M, Baldi S, Mari A, et al. Roux-en-Y gastric bypass and sleeve gastrectomy: mechanisms of diabetes remission and role of gut hormones. J Clin Endocrinol Metab. 2013;98:4391–4399. doi: 10.1210/jc.2013-2538.
    1. • Bojsen-Moller KN, Dirksen C, Jorgensen NB, et al. Early enhancements of hepatic and later of peripheral insulin sensitivity combined with increased postprandial insulin secretion contribute to improved glycemic control after Roux-en-Y gastric bypass. Diabetes. 2013; doi:10.2337/db13-1307. Insulin secretion increases after RYGB in patients with T2D, only in response to oral glucose, underscoring the importance of the changed gut anatomy
    1. Camastra S, Muscelli E, Gastaldelli A, et al. Long-term effects of bariatric surgery on meal disposal and b-cell function in diabetic and non-diabetic patients. Diabetes. 2013;62:3709–3717. doi: 10.2337/db13-0321.
    1. Brethauer SA, Aminian A, Romero-Talamás H, Batayyah E, Mackey J, Kennedy L, et al. Can diabetes be surgically cured? Long-term metabolic effectsof bariatric surgery in obese patients with type 2 diabetes mellitus. Ann Surg. 2013;258(4):628–636.
    1. Booth H, Khan O, Prevost T, Reddy M, Dregan A, Charlton J, et al. Incidence of type 2 diabetes after bariatric surgery: population-based matched cohort study. Lancet Diabetes Endocrinol. 2014;2(12):963–968. doi: 10.1016/S2213-8587(14)70214-1.
    1. Gourcerol G, St-Pierre DH, Taché Y. Lack of obestatin effects on food intake: should obestatin be renamed ghrelin-associated peptide (GAP)? Regul Pept. 2007;141(1–3):1–7. doi: 10.1016/j.regpep.2006.12.023.
    1. Seim I, Amorim L, Walpole C, Carter S, Chopin LK, Herington AC. Ghrelin gene-related peptides: multifunctional endocrine / autocrine modulators in health and disease. Clin Exp Pharmacol Physiol. 2010;37(1):125–131. doi: 10.1111/j.1440-1681.2009.05241.x.
    1. Siejka A, Jankiewicz-Wika J, Kołomecki K, Cywiński J, Piestrzeniewicz K, Swiętosławski J, Stępień H, Komorowski J. Long-term impact of vertical banded gastroplasty (VBG) on plasma concentration of leptin, soluble leptin receptor, ghrelin, omentin-1, obestatin, and retinol binding protein 4 (RBP4) in patients with severe obesity. Cytokine. 2013;64(2):490–493. doi: 10.1016/j.cyto.2013.07.026.
    1. Huda MS, Durham BH, Wong SP, Deepak D, Kerrigan D, McCulloch P, et al. Plasma obestatin levels are lower in obese and post-gastrectomy subjects, but do not change in response to a meal. Int J Obes. 2008;32:129–135. doi: 10.1038/sj.ijo.0803694.
    1. Margolskee RF. Molecular mechanisms of bitter and sweet taste transduction. J Biol Chem. 2002;277(1):1–4. doi: 10.1074/jbc.R100054200.
    1. Steensels S, Lannoo M, Avau B, Laermans J, Vancleef L, Farré R, Verbeke K, Depoortere I. The role of nutrient sensing in the metabolic changes after gastric bypass surgery. J Endocrinol. 2017;232(3):363–376. doi: 10.1530/JOE-16-0541.
    1. Avau B, Bauters D, Steensels S, Vancleef L, Laermans J, Lesuisse J, Buyse J, Lijnen HR, Tack J, Depoortere I. The gustatory signaling pathway and bitter taste receptors affect the development of obesity and adipocyte metabolism in mice. PLoS One. 2015;10:e0145538. doi: 10.1371/journal.pone.0145538.
    1. Margolskee RF, Dyer J, Kokrashvili Z, Salmon KS, Ilegems E, et al. T1R3 and gustducin in gut sense sugars to regulate expression of Na+-glucose co-transporter 1. PNAS. 2007;104:15075–15080. doi: 10.1073/pnas.0706678104.
    1. Liu R, Wei N, Guo W, Qiang O, Li X, Ou Y, et al. Octreotide alleviates obesity by reducing intestinal glucose absorption and inhibiting low-grade inflammation. Eur J Nutr. 2013;52(3):1067–1075. doi: 10.1007/s00394-012-0413-6.
    1. Rigamonti AE, Cella SG, Bonomo SM, Mancia G, Grassi G, Perotti M, et al. Effect of somatostatin infusion on peptide YY secretion: studies in the acute and recovery phase of anorexia nervosa and in obesity. Eur J Endocrinol. 2011;165(3):421–427. doi: 10.1530/EJE-11-0312.
    1. Farey JE, Preda TC, Fisher OM, Levert-Mignon AJ, Stewart RL, Karsten E, Herbert BR, Swarbrick MM, Lord RV. Effect of laparoscopic sleeve gastrectomy on fasting gastrointestinal, pancreatic, and adipose-derived hormones and on non-esterified fatty acids. Obes Surg. 2017;27(2):399–407. doi: 10.1007/s11695-016-2302-1.
    1. Korner J, Inabnet W, Conwell IM, Taveras C, Daud A, Olivero-Rivera L, et al. Differential effects of gastric bypass and banding on circulating guthormone and leptin levels. Obesity (Silver Spring) 2006;14(9):1553–1561. doi: 10.1038/oby.2006.179.
    1. Umeda LM, Silva EA, Carneiro G, Arasaki CH, Geloneze B, Zanella MT. Early improvement in glycemic control after bariatric surgery and itsrelationships with insulin, GLP-1, and glucagon secretion in type 2 diabeticpatients. Obes Surg. 2011;21(7):896–901. doi: 10.1007/s11695-011-0412-3.
    1. Owen BM, Mangelsdorf DJ, Kliewer SA. Tissue-specific actions of the metabolic hormones FGF15/19 and FGF21. Trends Endocrinol Metab. 2015;26:22e9. doi: 10.1016/j.tem.2014.10.002.
    1. Gomez-Ambrosi J, Gallego-Escuredo JM, Catalan V, Rodríguez A, Domingo P, Moncada R, Valentí V, Salvador J, Giralt M, Villarroya F, Frühbeck G. FGF19 and FGF21 serum concentrations in human obesity and type 2 diabetes behave differently after diet- or surgically-induced weight loss. Clin Nutr. 2017;36:861e868. doi: 10.1016/j.clnu.2016.04.027.
    1. de la Martinez Escalera L, Kyrou I, Vrbikova J, Hainer V, Sramkova P, Fried M, Piya MK, Kumar S, Tripathi G, McTernan PG. Impact of gut hormone FGF-19 on type-2 diabetes and mitochondrial recovery in a prospective study of obese diabetic women undergoing bariatric surgery. BMC Med. 2017;15(1):34. doi: 10.1186/s12916-017-0797-5.

Source: PubMed

Sponzoři a spolupracovníci

Zdravotní podmínky

Drogové intervence

3
Předplatit